Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Inclusion Criteria:

• Female or male patients at least 18 years of age
• Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
• Able and willing to provide informed consent and likely to complete all study visits
• All Fitzpatrick skin types will be evaluated

Exclusion Criteria:

• Known contraindications to Dermatix or any of its components
• Age of scar is > 4 months
• Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)